ExActa HIF prolyl hydroxylase inhibitors-The new lifestyle drug?

Acta Physiol (Oxf). 2019 Nov;227(3):e13370. doi: 10.1111/apha.13370. Epub 2019 Sep 17.

Authors

Lina K Sciesielski¹, Karin M Kirschner²

Affiliations

¹ Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Neonatology, Berlin, Germany.
² Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Vegetative Physiology, Berlin, Germany.

PMID: 31465609
DOI: 10.1111/apha.13370

No abstract available

Publication types

Editorial

MeSH terms

Anemia / drug therapy*
Anemia / etiology
Gene Expression Regulation, Enzymologic / drug effects
Humans
Hypoxia-Inducible Factor-Proline Dioxygenases / antagonists & inhibitors*
Hypoxia-Inducible Factor-Proline Dioxygenases / genetics
Hypoxia-Inducible Factor-Proline Dioxygenases / metabolism
Life Style
Physical Fitness
Prolyl-Hydroxylase Inhibitors / pharmacology*
Renal Insufficiency, Chronic / complications

Substances

Prolyl-Hydroxylase Inhibitors
Hypoxia-Inducible Factor-Proline Dioxygenases